Patients diagnosed with non-small cell lung cancer (NSCLC) may receive a variety of chemotherapy drugs as treatment for the disease. The purpose of this study is to find the highest dose of an investigational drug called BMS-936558 that can be given safely in patients with newly diagnosed NSCLC when used in combination with the drugs gemcitabine/cisplatin, pemetrexed/cisplatin, or carboplatin/paclitaxel.
BMS-936558 boosts the body’s immune system by targeting a protein on white blood cells called PD-1. PD-1 normally maintains the balance of the immune system by shutting it down at the right time. Some cancers take advantage of this shut-down mechanism by activating PD-1, enabling them to escape attack by the body’s white blood cells.
BMS-936558 binds to and inactivates PD-1, enhancing the body’s ability to detect and destroy cancer cells. It is hoped that by combining it with chemotherapy drugs, cancer cell death can be enhanced.